2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1045

Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Wrist in Rheumatoid Arthritis Patients Treated with Methotrexate, Intra-Articular Glucocorticoid and Adalimumab/Placebo
Abstract Number: 1006

Dynamic Gene Expression of Wnt Signaling Pathway During Osteogenic Stimulation in Vitro of Osteoarthritis Mesenchymal Stem Cells
Abstract Number: 726

Dynamic in Vivo Imaging of Th17-Mediated Osteoclastic Bone Resorption in Live Bones by Using Intravital Multiphoton Microscopy
Abstract Number: 2322

Dynamic Regulation of T Follicular Helper Cell Differentiation Through STAT Signaling
Abstract Number: 1127

Dynamic Stereo X-Ray Evaluation of Knee Joint Mechanics During Downhill Walking in Subject with Knee Osteoarthritis
Abstract Number: 1063

Dysfunction of Natural Killer and Natural Killer T Cells in Patients with Adult Onset Still’s Disease
Abstract Number: 416

Dyslipidaemia in Early Rheumatoid Arthritis Patients Is Common and Not Influenced by Two Years of Effective DMARD Therapy. the Opera Study
Abstract Number: 277

Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
Abstract Number: 2286

Dysregulated Discoidin Domain Receptor 2-Microrna 196a-Mediated Negative Feedback Against Excess Type I Collagen Expression in Scleroderma Dermal Fibroblasts
Abstract Number: 1490

Dysregulation of Angiogenic Homeostasis in Systemic Sclerosis
Abstract Number: 2223

Dysregulation of Chromatin Modification Enzymes in Psoriatic Arthritis
Abstract Number: 410

Early Growth Response-1 (EGR-1) Controls Synoviocyte Apoptosis, and Its Expression Is Regulated by the Direct Binding of Fibroblast Growth Factor-1 (FGF1) or Insulin-Like Growth Factor-1 (IGF1) to Integrin αvβ3
Abstract Number: 1343

EARLY Improvements in the Lower Limbs Enthesis by Ultrasound Predicting Later Favorable Responses in TNF Inhibotors-Treated Patients with Spondyloarthritis
Abstract Number: 1620

Early Magnetic Resonance Imaging Measures Independently Predict 1- and 2- Year X-Ray Progression: Results From a Large Clinical Trial
Abstract Number: 411

Early Menopause, Smoking and Circulating Antibodies Against Citrullinated Peptides in the Pre-Clinical Phase of Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].